ATRX and malignant colon neoplasm: We believe that the combination of the newly identified drugs targeting the RAD54-BLM interaction with conventional chemotherapeutic regimens might represent an attractive therapeutic option and, thereby, serve as adjunct therapy for patients with colon cancer.